Respiratory · VITD-RESP-03 · v2
When researchers ran trials built specifically to see whether vitamin D cuts asthma attacks, the result was no benefit, both in children [3] and in adults [4]. Other trials that counted attacks found no difference either [14],[18]. The one encouraging finding came only from a slice of a larger study, limited to people whose vitamin D was very low, and in a group that mixed asthma with another lung disease [17]. A few supportive hints came from very small pilot studies or from different measures such as symptom scores [16] or infection counts [11], not attacks themselves. So the evidence points against a general benefit, while leaving open a possible narrow benefit for the severely deficient.
The two trials designed with asthma exacerbation as a (co)primary endpoint were null: VDKA in children (adjusted HR 1.13, 95% CI 0.69-1.85) [3] and ViDiAs in adults (adjusted HR 1.02, 95% CI 0.69-1.53) [4]. Two further RCTs reported no difference in exacerbation number [14],[18]. The only positive exacerbation signal is a post hoc subgroup in older adults with asthma or COPD: overall null (HR 1.08, 95% CI 0.84-1.39) but HR 0.11 (95% CI 0.02-0.51) among those with baseline 25OHD <25 nmol/L [17]. Supportive-direction results elsewhere were on surrogate endpoints such as asthma control scores [16] or respiratory infections [11], or were non-significant pilots [12],[19],[10]. The contested point: The division is whether the severe-deficiency subgroup result in [17] reflects a real conditional effect or subgroup noise within an otherwise null trial in a mixed asthma/COPD population. The panel treats it as credible enough to prevent outright refutation but not to support the unconditional claim contradicted by the dedicated trials [3],[4].
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Vitamin D, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The two trials powered with exacerbation as a (co)primary endpoint — VDKA [3] in children and ViDiAs [4] in adults — are both null (HR 1.13 and 1.02), directly contradicting the claim.
The only positive exacerbation result [17] is a post-hoc subgroup analysis restricted to baseline 25OHD <25 nmol/L in a mixed asthma/COPD population; the overall analysis was null (HR 1.08). This supports at most a conditional effect in severe deficiency, not the unconditional claim.
Where it remains uncertain. A post hoc subgroup restricted to baseline 25OHD <25 nmol/L in a mixed asthma/COPD population was positive (HR 0.11) while the overall analysis was null (HR 1.08) [17].
Aleatory
Supportive-direction trials are small with wide, non-significant intervals, e.g. DIVA N=22 rate ratio 0.68 (95% CI 0.30-1.62) [12] and ABPA N=30, 0 vs 2 exacerbations P=0.16 [19].
Epistemic
The HR 0.11 benefit [17] rests on a post hoc subgroup with only 2.3% of participants below 25 nmol/L and has not been tested in a dedicated trial.
Inferential
Benefits on asthma control scores [16] or respiratory infections [11] do not directly establish fewer exacerbations.
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Most direct test (exacerbation = primary endpoint); null, and authors state findings do not support use to prevent exacerbations.
“vitamin D3 supplementation did not significantly improve the time to a severe exacerbation: the mean time to exacerbation was 240 days in the vitamin D3 group vs 253 days in the placebo group (mean group difference, -13.1 days [95% CI, -42.6 to 16.4]; adjusted hazard ratio, 1.13 [95% CI, 0.69 to 1.85]; P = .63)”
Panel auditInternal validity: high · scope of inference: Children aged 6-16 with persistent asthma, low vitamin D, on low-dose inhaled corticosteroids.Key limitations: terminated early for futility · restricted to low-vitamin-D children on ICS · point estimate slightly favours placebo
Adult exacerbation coprimary endpoint; null despite high baseline insufficiency.
“Vitamin D3 did not influence time to first severe exacerbation (adjusted HR 1.02, 95% CI 0.69 to 1.53, p=0.91)”
Panel auditInternal validity: high · scope of inference: Adults with asthma in London with high baseline vitamin D insufficiency, bolus dosing regimen.Key limitations: bolus (intermittent) dosing regimen · no effect modification by baseline status or genotype · single-city adult population
Favourable direction on an exacerbation proxy but non-significant underpowered pilot (N=22).
“Group oral corticosteroids rates were 0.82 and 1.18/child, intervention versus control (rate ratio = 0.68; 95 % CI: 0.30, 1.62; non-significant)”
Panel auditInternal validity: low · scope of inference: Preschool children with viral-induced asthma over 6 winter months.Key limitations: pilot, not powered for exacerbations · wide CI spanning benefit and harm · exacerbation proxy (oral corticosteroid rate)
Prenatal prevention of asthma onset (different construct), non-significant; does not test exacerbation reduction in established asthma.
“98 of 405 (24.3%; 95% CI, 18.7%-28.5%) in the 4400-IU group vs 120 of 401 (30.4%, 95% CI, 25.7%-73.1%) in the 400-IU group (hazard ratio, 0.8; 95% CI, 0.6-1.0; P = .051)”
Panel auditInternal validity: high · scope of inference: Prenatal vitamin D dosing and prevention of childhood asthma/recurrent wheeze through age 3.Key limitations: prevention outcome, not exacerbations · high-dose vs low-dose comparison (no true placebo) · primary result non-significant (P=.051)
4 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Direct exacerbation-endpoint RCTs contradict the general claim, while a credible deficiency-subgroup signal prevents outright refutation.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Severe-deficiency exacerbation RCT. The sole positive signal [17] is a post hoc subgroup in a mixed population; it has never been the primary hypothesis of a trial. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised trial enrolling only asthma patients with baseline 25OHD <25 nmol/L, powered on time-to-exacerbation.
Open question: Does vitamin D supplementation reduce exacerbations specifically in asthma patients with baseline 25OHD <25 nmol/L? Why it is still open: The only positive result [17] is a post hoc subgroup in a mixed asthma/COPD cohort where just 2.3% were below 25 nmol/L; the overall analysis was null (HR 1.08).
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19